Organic compounds -- part of the class 532-570 series – Organic compounds – Heavy metal containing
Reexamination Certificate
2010-03-11
2011-10-11
Gonzalez, Porfirio Nazario (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heavy metal containing
C556S026000, C514S492000, C424S649000
Reexamination Certificate
active
08034964
ABSTRACT:
The present invention provides phosphaplatins, stable isolated monomeric phosphato complexes of platinum (II) and (IV), and methods of use thereof for treating cancers, including cisplatin- and carboplatin-resistant cancers. Unlike cisplatin, these complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes—unlike cisplatin, carboplatin, and related platinum-based anti-cancer agents—do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum anticancer agents that have a different molecular target than those in the art.
REFERENCES:
patent: 4234500 (1980-11-01), Hoeschel
patent: 4291027 (1981-09-01), Hoeschel
patent: 7342122 (2008-03-01), Odani
patent: 0409527 (1991-01-01), None
patent: 2177525 (2010-04-01), None
patent: 2005/000858 (2005-01-01), None
Mishur et al., “INOR 135Platinum-(IV) phosphate complexes as potential anticancer drugs”, (posted on ACS website Jul. 17, 2006).
Bose et al., Poster, “Platinum(IV) Phosphato Complexes as Potential Anticancer Drugs”, Displayed at ACS National Meeting, Sep. 10-14, 2006.
Bose et al., Inorg. Chem., vol. 29, No. 18, pp. 3461-3467 (1990).
Siddik ZH, “Cisplatin: mode of cytotoxic action and molecular basis of resistance, Oncongene,” 22:7265-7279 (2003).
Slavin et al., “One- and Two-Dimensional 31P NMR Characterization of Pure Phosphato Chelates in Cytidine-5′-di- and -tri-phosphatoplatinum (II) complexes,” J. Chem. Soc. Chem. Comm., 1256-1258 (1990).
Slavin et al., “Phosphonato Complexes of Platinum (II): Kinetics of Formation and Phosphorus-31 NMR Studies,” J. Inorg. Biochem., 40, 339-347 (1990).
Sorenson CM et al., “Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks,” Cancer Res, 48:4484-4488 (1988).
Stanko, J.A., results quoted by M. J. Cleare in “Platinum Coordination Complexes in Cancer Chemotherapy” (T. A. Connors and J. J. Roberts, Eds.), Springer-Verlag: New York, 1974; pp. 25-26.
Sulis et al., “PTEN: from pathology to biology,” Trends Cell Biol, 13, 478-83 (2003).
Vaisman et al., “Cell Cycle Changes Associated With Formation of Pt-DNA Adducts in Human Ovarian Carcinoma Cells With Different Cisplatin Sensitivity,” Cytometry 27:54-64 (1997).
Vleminckx et al., “Genetic manipulation of E-cadherin expression by epithelial tumour cells reveals an invasion suppressor role,” Cell, 66, 107-119 (1991).
Wang et al., “Cellular Processing of Platinum Anticancer Drugs,” Nature Reviews Drug Discovery, 4, 307-320 (Apr. 2005).
Wei SQ et al., “Role of ERK1/2 kinase in cisplatin-induced apoptosis in human ovarian carcinoma cells,” Chin Med Sci J, 19:125-129 (2004).
Welters MJ et al., “Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo,” Br J Cancer, 79:82-88 (1999).
Wernyj RP et al., “Molecular mechanisms of platinum resistance: still searching for the Achilles' heel,” Drug Resist Updat, 7:227-232 (2004).
Wesseling et al., “Angiogenesis in brain tumors; pathobiological and clinical aspects,” J. Neurooncol., 32:253-265 (1997).
Wood FE et al., “195Pt and 31P nuclear magnetic resonance studies of the binding of the cis-Pt(NH3)2+2 moiety to phosphate in aqueous solution,” Inorganica Chimica Acta, 67:L19 (1982).
Zhang et al., “Differential sensitivity of human glioblastoma LN18 (PTEN-positive) and A172 (PTEN-negative) cells to Taxol for apoptosis,” Brain Res., 1239:216-225 (2008).
International Search Report and Written Opinion in PCT/US2008/072398, mailed Mar. 5, 2009 (10 pages).
Extended European Search Report in EP08797320.2, mailed Sep. 28, 2010 (7 pages).
Abe et al., “PTEN Decreases in Vivo Vascularization of Experimental Gliomas in Spite of Proangiogenic Stimuli,” Cancer Research, 63, 2300-2305 (2003).
Appleton TG et al., “Multinuclear NMR study of reactions of methylphosphonic acid, CH3PO3H2, and (aminoalkyl) phosphonic acids, NH2(CH2)nPO3H2 (n=1-3), with the cis-diamminediaquaplatinum(II) cation and cis-diamminedihydroxoplatinum(II),” Inorganic Chemistry, 25:720-725 (1986).
Belka C et al., “Why ‘radiation oncology,’” Radiat Oncol, 1:1 (2006).
Beneteau, Marie et al., “Localization of Fas/CD95 into the Lipid Rafts on Down-Modulation of the Phosphatidylinositol 3-Kinase Signaling Pathway,” Mol Cancer Res 2008; 6(4), 604-613 (Apr. 2008).
Birchmeier et al , “Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness,” Biochim. Biophys. Acta, 1198, 11-26 (1994).
Bose et al., Poster, “Platinum Phosphato Complexes: How They Might Work as Anticancer Agents,” displayed ACS National Meeting, Mar. 25, 2007.
Bose et al., “Kinetics and Mechanisms of Platinum (II) Promoted Hydrolysis of Inorganic Polyphosphates,” Inorg. Chem., 24, 3989-3996 (1985).
Bose et al., “Multinuclear NMR Studies and the Kinetics of Formation of Platinum (II)-Adenine Nucleotide Complexes,” J. Am. Chem. Society, 1986, 108, 4403-4408.
Bose et al., “Phosphorus-31 NMR and Kinetic Studies of the Formation of Ortho-, Pyro- and Tri-phosphato Complexes of cis-Dichlorodiammineplatinum (II),” J. Am. Chem. Soc., 106, 3336-3343 (1984).
Bose et al., “Platinum (II) Catalyzed Hydrolysis of Pyrophosphate and Triphosphate: Phosphorus-31 NMR Characterization of Kinetic Intermediates,” Inorg. Chem., 23, 1181-1183 (1984).
Calvert et al., “Early Clinical Studies with cis-Diammine-1,1-Cyclobutane Dicarboxylate Platinum II,” Cancer Chemother Pharmacol 9: 140-147 (1982).
Carmeliet, P., “Angiogenesis in life, disease, and medicine,” Nature 438, 932-936 (2005).
Cavallaro et al., “Cadherins and the tumour progression: is it all in a switch?,” Cancer Letters, 176, 123-128 (2002).
Christian et al., Abstract #291, “Phase I and Pharmacologic Study of Ormaplatin (OP)/Tetraplatin,” Proceedings of ASCO, vol. 11, Mar. 1992.
Coll M et al., “Molecular structure of the complex formed between the anticancer drug cisplatin and d(pGpG):C222(1) crystal form,” J Biomol Struct Dyn, 8:315-330 (1990).
Cully et al., “Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis,” Nature Rev., 6, 184-192 (2006).
Creaven, et al., “Phase I Clinical Trial of cis-Dichloro-trans-dihydroxy-bis-isopropylamine platinum (IV) (CHIP),” Cancer Treat Rep 67: 795-800 (1983).
Eastman, A., “Activation of Programmed Cell Death by Anticancer Agents: Cisplatin as a Model System,” Cancer Cells, vol. 2, No. 8-9, 275-280 (1990).
Eiyassaki et al., “Lipid-rafts mediate ultraviolet light-induced fas aggregation in M624 melanoma cells,” Photochemistry and Photobiology, 82:787-792 (2006).
Extra et al., “Phase I study of oxaliplatin in patients with advanced cancer,” Cancer Chemother Pharmacol 25: 299-303 (1990).
Folkman et al., “Angiogenesis in cancer, vascular, rheumatoid and other disease,” Nat. Med., 1:27-31 (1995).
Frixen et al., “E-Cadherin-mediated Cell-Cell Adhesion Prevents Invasiveness of Human Carcinoma Cells,” J. Cell. Biol., 113, 173-185 (1991).
Galanski M., “Recent developments in the field of anticancer platinum complexes,” Recent Pat Anticancer Drug Discov, 1:285-295 (2006).
Giaver et al., “Chemogenomic profiling: identifying the functional interactions of small molecules in yeast,”
Dinsmore & Shohl LLP
Gonzalez Porfirio Nazario
Ohio University
LandOfFree
Phosphaplatins and their use in the treatment of cancers... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phosphaplatins and their use in the treatment of cancers..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphaplatins and their use in the treatment of cancers... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4261692